|
|
Article: Nanobiotix and BiotechCorp Announce Initial Focus of Their Collaboration: P-O-C Diagnostics and Drug Delivery Systems for Tropical Diseases, Such as Malaria.
- Article from:
- Cancer Weekly
- Article date:
- October 7, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Nanobiotix, an emerging nanomedicine company focused on cancer therapy, announced that the Company and its partner, Malaysian Biotechnology Corporation Sdn Bhd (BiotechCorp), will initially focus their collaboration on developing point-of-care (P-O-C) diagnostics and drug delivery systems for tropical diseases, such as malaria. BiotechCorp has acquired an exclusive, global license to a Nanobiotix nanotechnology platform for non-cancer purposes. As part of the collaboration, three BiotechCorp scientists will take up residence at Nanobiotix for a period of 12 months to undergo the technology transfer training (see also Nanobiotix).
Malaria is a disease that can be ...